We are live on ! Find out more
MWNA

Marshall Wace North America Portfolio holdings

AUM $23.5B
1-Year Est. Return 46.46%
This Fund
S&P 500
This Quarter Est. Return
+21.94%
1 Year Est. Return
+46.46%
3 Year Est. Return
+109.4%
5 Year Est. Return
10 Year Est. Return
AUM
$22.2B
AUM Growth
+$6.6B
Cap. Flow
+$3.75B
Cap. Flow %
16.89%
Top 10 Hldgs %
18.16%
Holding
1,735
New
565
Increased
342
Reduced
340
Closed
467

Top Sells

Rank Stock Value
1
ADBE icon
Adobe
ADBE
+$183M
2
ABBV icon
AbbVie
ABBV
+$149M
3
HUM icon
Humana
HUM
+$120M
4
FIS icon
Fidelity National Information Services
FIS
+$119M
5
MELI icon
Mercado Libre
MELI
+$103M

Sector Composition

Rank Sector Weight
1 Healthcare 27.33%
2 Technology 17.93%
3 Consumer Discretionary 11.98%
4 Financials 8.85%
5 Communication Services 8.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CVA
1701
DELISTED
Covanta Holding Corporation
CVA
-205,299
Closed -$1.59M
FLXN
1702
DELISTED
Flexion Therapeutics, Inc.
FLXN
-97,531
Closed -$1.01M
CORE
1703
DELISTED
Core Mark Holding Co., Inc.
CORE
-35,109
Closed -$1.02M
PFPT
1704
DELISTED
Proofpoint, Inc.
PFPT
-46,822
Closed -$4.94M
QTS
1705
DELISTED
QTS REALTY TRUST, INC.
QTS
-4,534
Closed -$285K
MXIM
1706
DELISTED
Maxim Integrated Products
MXIM
-25,328
Closed -$1.71M
TLND
1707
DELISTED
Talend S.A. American Depositary Shares
TLND
-19,219
Closed -$749K
GRUB
1708
DELISTED
Just Eat Takeaway.com N.V. American Depositary Shares
GRUB
-12,348
Closed -$1.79M
CLGX
1709
DELISTED
Corelogic, Inc.
CLGX
-129,758
Closed -$8.78M
PRSP
1710
DELISTED
Perspecta Inc. Common Stock
PRSP
-56,944
Closed -$1.11M
HMSY
1711
DELISTED
HMS Holdings Corp.
HMSY
-10,073
Closed -$242K
OXFD
1712
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
-24,556
Closed -$287K
EV
1713
DELISTED
Eaton Vance Corp.
EV
-27,306
Closed -$1.04M
OSB
1714
DELISTED
Norbord Inc.
OSB
-16,900
Closed -$498K
CXO
1715
DELISTED
CONCHO RESOURCES INC.
CXO
-1,156,106
Closed -$51M
PE
1716
DELISTED
PARSLEY ENERGY INC
PE
-5,206,225
Closed -$48.7M
BMY.RT
1717
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
-1,862,165
Closed -$3.97M
MYOK
1718
DELISTED
MyoKardia, Inc. Common Stock
MYOK
-179,629
Closed -$24.5M
WMGI
1719
DELISTED
Wright Medical Group Inc
WMGI
-57,515
Closed -$1.76M
BITA
1720
DELISTED
Bitauto Holdings Limited
BITA
-71,294
Closed -$1.12M
IMMU
1721
DELISTED
Immunomedics Inc
IMMU
-36,044
Closed -$3.06M
AIMT
1722
DELISTED
Aimmune Therapeutics
AIMT
-20,702
Closed -$713K
ETFC
1723
DELISTED
E*Trade Financial Corporation
ETFC
-27,820
Closed -$1.39M
CBPO
1724
DELISTED
China Biologic Products Holdings, Inc.
CBPO
-16,978
Closed -$1.89M
COWN
1725
DELISTED
Cowen Inc. Class A Common Stock
COWN
-49,600
Closed -$808K

Similar funds

Marshall Wace North America's Q4 2020 Portfolio in Review

As of Q4 2020, Marshall Wace North America held 1,735 positions worth $22.2B, up 42% from $15.6B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Marshall Wace North America deployed $3.75B of net new capital in Q4 2020, opening 565 new positions and adding to 342 existing holdings. Its largest new stake was ExxonMobil: 2,686,885 shares worth $111M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 28% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Adobe, an estimated $183M trimmed.

  • Marshall Wace North America's largest Q4 2020 buy was ExxonMobil: 2,686,885 shares worth $111M.
  • Marshall Wace North America added most to Thermo Fisher Scientific in Q4 2020, an estimated $239M increase.
  • Marshall Wace North America's biggest Q4 2020 reduction was Adobe, cutting an estimated $183M.
  • Marshall Wace North America fully exited Baxter International in Q4 2020, selling an estimated $92.8M.
  • Marshall Wace North America's ten largest holdings make up 18% of its $22.2B portfolio in Q4 2020.
  • Marshall Wace North America opened 565 new positions and closed 467 in Q4 2020.
  • Marshall Wace North America's portfolio value rose 42% quarter-over-quarter to $22.2B.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.